Gamma-glutamyl transferase expression in higher-grade astrocytic glioma.
Increased expression of gamma-glutamyltransferase (GGT) has been detected in a range of human malignancies and is thought to be involved in neoplastic proliferation and treatment resistance. Since GGT expression and its role in malignant glioma biology remain largely unknown, we investigated this phenomenon by immunostaining 26 higher-grade human astrocytic gliomas (WHO grades III and IV) with a monoclonal anti-GGT-antibody (138H11). Further, human pancreatic GGT cDNA was used for liposome-mediated transfection of 9L gliosarcoma cells. GGT-expressing and control 9L cells were cultured in media containing different amounts of essential amino acids and/or cytotoxic agents. Cell viability was evaluated by microplate MTT assay. Immunohistochemical staining of tumor specimens demonstrated that GGT expression is a frequent feature of higher-grade human astrocytic gliomas, but not of normal brain tissue. Human tumors were strongly GGT-positive in 6 of 7 cases of grade III astrocytoma, and in 12 of 19 grade IV astrocytoma (glioblastoma multiforme, GBM) cases. In the cell culture model, 9L-GGT cells had a growth advantage over control cells in cysteine-deficient medium. but not in standard or glutamine-free medium. No significant difference in numbers of viable cells of either clone was found in media containing the alkylating drug BCNU (5-200 microg/ml). In conclusion, GGT is expressed in a high percentage of human WHO grade III astrocytomas and GBM, but not in normal brain tissue. This molecule seems to give neoplastic cells a moderate growth advantage under in vivo conditions.
Schäfer
C
C
Department of Neurosurgery, Martin-Luther-University Halle-Wittenberg, Germany.
Fels
C
C
Brucke
M
M
Holzhausen
H J
HJ
Bahn
H
H
Wellman
M
M
Visvikis
A
A
Fischer
P
P
Rainov
N G
NG
D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D001921:Brain / Q000201:enzymology; D002330:Carmustine / Q000494:pharmacology; D002455:Cell Division; D002999:Clone Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D003470:Culture Media / Q000494:pharmacology; D003545:Cysteine / Q000494:pharmacology; D018076:DNA, Complementary / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D004790:Enzyme Induction; D005260:Female; D005909:Glioblastoma / Q000201:enzymology* / Q000235:genetics; D018316:Gliosarcoma / Q000473:pathology; D005973:Glutamine / Q000494:pharmacology; D006801:Humans; D008081:Liposomes; D008297:Male; D016253:Microscopy, Immunoelectron; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology; D005723:gamma-Glutamyltransferase / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology
D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D003470:Culture Media; D018076:DNA, Complementary; D008081:Liposomes; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D011993:Recombinant Fusion Proteins; D005973:Glutamine; D005723:gamma-Glutamyltransferase; D003545:Cysteine; D002330:Carmustine